Table 1.
Demographics of study patients.
| HC (n = 200) | Sar (n = 215) | HP (n = 30) | (E)GPA (n = 11) | IPF (n = 68) | |
|---|---|---|---|---|---|
| Age a | 46.6 ± 9.2 | 48.2 ± 11.8 | 59.6 ± 9.5 | 54.7 ± 13.9 | 69.5 ± 8.9 |
| Sex (male) | 92 (46) | 117 (54) | 15 (50) | 7 (64) | 60 (88) |
| Ethnicity (White) | 190 (89) | 30 (100) | 11 (100) | 67 (99) | |
| Smoker (Never) | 105 (49) | 13 (43) | 4 (36) | 16 (24) | |
| Immunosuppressive medication | 0 | 101 (47) | 12 (40) | 6 (55) | 0 |
| CRP (mg/L) | 2.0 IQR 4.0 | 2.0 IQR 4.0 | 2.0 IQR 23.0 | 3.5 IQR 5.0 | |
| FVC % predicted | 94.3 ± 20.3 | 78.5 ± 21.7 | 90.0 ± 21.2 | 80.1 ± 20.1 | |
| FEV1 % predicted | 84.9 ± 21.5 | 81.2 ± 22.0 | 86.2 ± 20.1 | 82.9 ± 18.3 | |
| DLCO % predicted | 73.5 ± 17.4 | 46.8 ± 13.8 | 58.9 ± 20.2 | 41.5 ± 11.4 | |
| Scadding stage | NA | NA | NA | ||
| 0 | 44 (21) | ||||
| I | 45 (21) | ||||
| II | 50 (23) | ||||
| III | 32 (15) | ||||
| IV | 40 (19) | ||||
| Unknown | 4 (2) |
Values are shown as absolute numbers with percentages in brackets; a Age, FVC % predicted, FEV1 % predicted and DLCO % predicted are shown as mean ± std. CRP, is shown as median IQR.; Medication consisted of immunosuppressive medication including prednisone, methotrexate, azathioprine, infliximab, leflunomide, adalumimab, hydroxychloroquine and cellcept.; CRP was available from 207 sarcoidosis patients, 27 HP patients, 9 (E)GPA patients and 68 IPF patients.; FVC was available from 166 sarcoidosis patients, 27 HP patients, 11 (E)GPA patients and 59 IPF patients; FEV1 was available from 174 sarcoidosis patients, 26 HP patients, 11 (E)GPA patients and 60 IPF patents; DLCO was available from 160 sarcoidosis patients, 25 HP patients, 7 (E)GPA patients and 55 IPF patients; HC: healthy control, Sar: sarcoidosis, HP: hypersensitivity pneumonitis, (E)GPA: (eosinophilic) granulomatosis with polyangiitis ((E)GPA), IPF: idiopathic pulmonary fibrosis, CRP: C-reactive protein, FVC: Forced vital capacity, FEV1: Forced expiratory volume in 1 s, DLCO: Diffusing capacity.